Remarkable Intracranial Response to Sotorasib in a Patient With KRASG12C-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report

Justin Yeh, MD; Jennifer A. Marks, MD; Ali H. Alzeer, MD; Emily A. Sloan, MD, PhD; Reshma Varghese, MD; Nitika Paudel, MD, PhD; Joshua E. Reuss, MD; Peter J. Bergquist, MD; Stephen V. Liu, MD; Chul Kim, MD, MPH

JTO Clinical and Research Reports (Dec 2022)

Remarkable Intracranial Response to Sotorasib in a Patient With KRASG12C-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report

Justin Yeh, MD,
Jennifer A. Marks, MD,
Ali H. Alzeer, MD,
Emily A. Sloan, MD, PhD,
Reshma Varghese, MD,
Nitika Paudel, MD, PhD,
Joshua E. Reuss, MD,
Peter J. Bergquist, MD,
Stephen V. Liu, MD,
Chul Kim, MD, MPH

Affiliations

Justin Yeh, MD: Department of Medicine, MedStar Georgetown University Hospital, Washington, District of Columbia
Jennifer A. Marks, MD: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia
Ali H. Alzeer, MD: Department of Pathology and Laboratory Medicine, MedStar Georgetown University Hospital, Washington, District of Columbia
Emily A. Sloan, MD, PhD: Department of Pathology and Laboratory Medicine, MedStar Georgetown University Hospital, Washington, District of Columbia
Reshma Varghese, MD: Department of Medicine, MedStar Georgetown University Hospital, Washington, District of Columbia
Nitika Paudel, MD, PhD: Department of Radiation Oncology, MedStar Georgetown University Hospital, Washington, District of Columbia
Joshua E. Reuss, MD: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia
Peter J. Bergquist, MD: Department of Radiology, MedStar Georgetown University Hospital, Washington, District of Columbia
Stephen V. Liu, MD: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia
Chul Kim, MD, MPH: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia; Corresponding author. Address for correspondence: Chul Kim, MD, Division of Hematology and Oncology, Georgetown Lombardi Comprehensive Cancer Center, 3800 Reservoir Road Northwest, Washington, DC 20007.

Journal volume & issue: Vol. 3, no. 12
p. 100428

Abstract

Read online

Sotorasib is a KRASG12C inhibitor that recently received approval for use in locally advanced or metastatic KRASG12C-mutated NSCLC. CodeBreaK100, the phase 2 clinical trial leading to the approval of sotorasib, excluded patients with untreated brain metastases; there have been no reports describing efficacy of sotorasib on untreated brain metastases. We present a case of a patient with active untreated brain metastases with resulting disorientation and weakness who has radiographic response and complete resolution of neurologic symptoms with sotorasib. Our case illustrates the intracranial activity of sotorasib, but additional studies are needed to characterize the intracranial response rate and duration of response in these patients.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords